Talecris Immunoglobulin Therapy Gains Priority Review For CIDP
This article was originally published in The Pink Sheet Daily
Executive Summary
Supplemental BLA for chronic inflammatory demyelinating polyneuropathy has Sept. 13 user fee date.
You may also be interested in...
Talecris’ Gamunex Gets Leg Up In CIDP
Immune globulin’s broader label sure to please merger-bound CSL.
Talecris’ Gamunex Gets Leg Up In CIDP
Immune globulin’s broader label sure to please merger-bound CSL.
Bayer To Retain Kogenate Line Following Plasma Unit Spin-Off
Company divests plasma products business to NPS BioTherapeutics under a $590 mil. agreement. Bayer will receive 10% equity in NPS, a new corporation formed by Cerebus Capital Management and Ampersand Ventures.